Calcium phosphate dihydrate API Manufacturers

General Description:

Calcium phosphate dihydrate is a chemical compound identified by the CAS number 7789-77-7. It is known for its distinct pharmacological properties and applications.

Indications:

This drug is primarily indicated for: For use as an over the counter calcium and phosphate supplement, antacid, or a source of calcium and phosphate in toothpaste . Its use in specific medical scenarios underscores its importance in the therapeutic landscape.

Pharmacodynamics:

Calcium phosphate dihydrate exerts its therapeutic effects through: Calcium phosphate reacts with acid in the stomach to raise the pH . In toothpaste it provides a source of calcium and phosphate ions to support remineralization of the teeth . As a supplement it provides a source of calcium and phospate, both of which are important ions in bone homeostasis. The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.

Mechanism of Action:

Calcium phosphate dihydrate functions by: The phosphate ions in calcium phosphate likely react with hydrochloric acid in the stomach to neutralize the pH. In toothpaste and in systemic circulation, calcium phosphate provides a source of calcium and phosphate ions to support remineralization of the teeth and bone homeostasis respectively. The increase in plasma calcium reduces calcium flux from osteocyte activity by reducing the secretion of parathyroid hormone (PTH) . Calcium does this by stimulating a G-protein coupled calcium receptor on the surface of parathyroid cells. The reduction in calcium flux increases the amount of calcium deposited in bone resulting in an increase in bone mineral density. The reduction in PTH secretion also reduces the amount of vitamin D metabolized to its active form, calcidiol. Since calcidiol increases the expression of calcium dependent ATPases and transient receptor potential cation channel subfamily V member 6 (TRPV6) both of which are involved in calcium uptake from the gut, a reduction in calcidiol results in less calcium absorption. Additionally, TRPV5, the channel responsible for calcium reabsorption in the kidney, is downregulated when PTH secretion is reduced thus increasing calcium excretion via the kidneys. Another hormone, calitonin, is likely involved in the reduction of bone resorption during periods of high plasma calcium. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.

Classification:

Calcium phosphate dihydrate belongs to the class of inorganic compounds known as alkaline earth metal phosphates. These are inorganic compounds in which the largest oxoanion is phosphate, and in which the heaviest atom not in an oxoanion is an alkaline earth metal, classified under the direct parent group Alkaline earth metal phosphates. This compound is a part of the Inorganic compounds, falling under the Mixed metal/non-metal compounds superclass, and categorized within the Alkaline earth metal oxoanionic compounds class, specifically within the Alkaline earth metal phosphates subclass.

Categories:

Calcium phosphate dihydrate is categorized under the following therapeutic classes: Acids, Acids, Noncarboxylic, Calcium Compounds, Phosphate salts, Phosphoric Acids, Phosphorus Acids, Phosphorus Compounds. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.